triazoles has been researched along with Kaposi Sarcoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, M; Dandekar, S; Davis, RR; Izumiya, Y; Jiang, G; Li, Y; Lyu, Y; Maverakis, E; Nakano, K; Olney, L; Shimoda, M; Tepper, CG; Tran, K; Zhou, F | 1 |
| Chen, HS; De Leo, A; Hills, R; Kerekovic, A; Lieberman, PM; Wang, Z | 1 |
| Brown, M; O'Reilly Zwald, F | 1 |
| Aglietta, M; Arese, M; Barra, L; Benelli, R; Bussolino, F; Ghigo, D; Montrucchio, G; Primo, L; Rola-Pleszczynski, MR; Sanavio, F | 1 |
| Albini, A; Biancone, L; Boccellino, M; Bussolati, B; Camussi, G; Cantaluppi, V; Conaldi, PG; Del Sorbo, L; Toniolo, A | 1 |
1 review(s) available for triazoles and Kaposi Sarcoma
| Article | Year |
|---|---|
Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients.
Topics: Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Education, Medical, Continuing; Female; Humans; Immunocompromised Host; Incidence; Male; Melanoma; Organ Transplantation; Prognosis; Pyrimidines; Risk Assessment; Sarcoma, Kaposi; Sirolimus; Skin Neoplasms; Survival Analysis; Treatment Outcome; Triazoles; Voriconazole | 2011 |
4 other study(ies) available for triazoles and Kaposi Sarcoma
| Article | Year |
|---|---|
Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.
Topics: Animals; Azepines; Cell Line, Tumor; Diterpenes; DNA Replication; Herpesvirus 8, Human; Humans; Lymphoma, Primary Effusion; Mice; NF-kappa B; Oncolytic Virotherapy; Oncolytic Viruses; Sarcoma, Kaposi; Triazoles; Virus Replication; Xenograft Model Antitumor Assays | 2017 |
BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency.
Topics: Antigens, Viral; Azepines; B-Lymphocytes; Binding Sites; Cell Cycle Proteins; Cell Line, Tumor; DNA-Binding Proteins; Gene Expression Regulation, Viral; HEK293 Cells; Herpesvirus 8, Human; Humans; Immediate-Early Proteins; Nuclear Proteins; Phosphoproteins; Pleural Effusion, Malignant; Protein Binding; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Sarcoma, Kaposi; Trans-Activators; Transcription Factors; Triazoles; Virus Activation; Virus Latency | 2017 |
Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis.
Topics: Aged; Animals; Azepines; Base Sequence; Cell Line; Chemotaxis; Choriocarcinoma; Collagen; Culture Media, Conditioned; Cytokines; Dogs; Drug Combinations; Endothelium, Vascular; Female; Growth Substances; Humans; Interleukin-1; Laminin; Lymphoma, Large B-Cell, Diffuse; Macrophages; Male; Mice; Mice, Inbred DBA; Molecular Sequence Data; Neoplasm Proteins; Neovascularization, Pathologic; Platelet Activating Factor; Platelet Membrane Glycoproteins; Proteoglycans; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Sarcoma, Kaposi; Skin Neoplasms; Thrombin; Triazoles; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Umbilical Veins; Uterine Neoplasms | 1995 |
Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis.
Topics: Azepines; Cell Movement; Diterpenes; Dose-Response Relationship, Drug; Fibrinolytic Agents; Gene Products, tat; Ginkgolides; HIV-1; Humans; Lactones; Phospholipid Ethers; Platelet Activating Factor; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Pyridinium Compounds; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Sarcoma, Kaposi; tat Gene Products, Human Immunodeficiency Virus; Triazoles; Tumor Cells, Cultured | 1999 |